Novavax (NVAX) Gross Profit (2011 - 2026)

Novavax's Gross Profit history runs 11 years deep, the most recent figure standing at $108.8 million for Q1 2026.

• In Q1 2026, Gross Profit fell 83.32% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $442.5 million (down 59.68% YoY), while the FY2025 annual figure was $1.1 billion, up 119.1% from the prior year.
• Gross Profit was $108.8 million for Q1 2026 at Novavax, down from $125.0 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $688.8 million in Q1 2022 to a low of -$85.2 million in Q2 2022.
• Historically, Gross Profit has averaged $193.7 million across 5 years, with a median of $125.0 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Gross Profit plunged 128.57% in 2022, then surged 1783.45% in 2025.
• A 5-year view of Gross Profit shows it stood at $175.6 million in 2022, then decreased by 22.36% to $136.4 million in 2023, then tumbled by 62.13% to $51.6 million in 2024, then surged by 142.12% to $125.0 million in 2025, then retreated by 12.97% to $108.8 million in 2026.
• The last three Gross Profit figures came in at $108.8 million (Q1 2026), $125.0 million (Q4 2025), and $48.9 million (Q3 2025), per Business Quant data.